Patient info Open main menu

Brabio 40 mg/ml solution for injection in pre-filled syringe – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
40 mg / ml
Contains active substance:

Patient leaflet - Brabio 40 mg / ml solution for injection Pre-filled syringe

1. What Brabio is and what it is used for

Brabio is a medicine used for the treatment of relapsing forms of multiple sclerosis (MS). It modifies the way in which your body's immune system works and it is classed as an immunomodulating agent. The symptoms of multiple sclerosis (MS) are thought to be caused by a defect in the body's immune system. This produces patches of inflammation in the brain and spinal cord. Brabio is used to reduce the number of times you suffer attacks of MS (relapses). It has not been demonstrated to help if you have any form of MS which does not have relapses, or hardly any relapses. Brabio may not have any effect on the length of time an MS attack lasts, or how badly you suffer during an attack.

2. What you need to know before you use Brabio

Do not use Brabio

  • If you are allergic to glatiramer acetate

    or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before using Brabio

  • if you have any kidney or heart problems

    as you may need to have regular tests and check-ups.

  • if you have or have had any liver

    problems (including those due to alcohol consumption).

Brabio can cause severe allergic reactions, some of which may be life-threatening. These reactions may occur shortly after administration, even months up to years after starting treatment and even if previous administrations were without allergic reactions. The signs and symptoms of allergic reactions may overlap with post-injection reactions. Your doctor will inform you on the signs of an allergic reaction.

Children

Brabio is not to be used in children below the age of 18 years.

Elderly

Brabio has not been specifically studied in the elderly. Please ask your doctor for advice. Other medicines and Brabio

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice and consideration regarding brabio treatment during pregnancy. Brabio may be used during pregnancy upon advice from your doctor.

Limited data in humans showed no negative effects of glatiramer acetate on breastfed newborns/infants. Brabio can be used during breast-feeding.

Driving and using machines

Brabio is not known to influence the ability to drive or operate machinery.

3. How to use Brabio

Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose in adults is one pre-filled syringe (40 mg of glatiramer acetate), administered under the skin (subcutaneously) three times a week, injected at least 48 hours apart, for example Monday Wednesday and Friday. It is recommended to administer the drug on the same days every week. It is very important to inject Brabio properly:

  • Into the tissue under the skin

    (subcutaneous tissue) only (see "Instructions for Use" below).

  • At the dose instructed by your doctor. Use

    only the dose prescribed by your doctor.

  • Never use the same syringe more than

    once. Any unused product or waste must be discarded.

    • Do not mix or co-administer the content of

      Brabio pre-filled syringes with any product.

    • If the solution contains particles, do not use it. Use a new syringe.

The first time you use Brabio you will be given full instructions and will be supervised by a doctor or nurse. They will be with you while you give yourself the injection and for half an hour afterwards, just to make sure you do not have any problems.

Instructions for use

Read these instructions carefully before using Brabio.

Before the injection, make sure you have everything you need:

  • One blister with one Brabio pre-filled syringe
  • Disposal unit for used needles and syringes.
  • For each injection, take only one blister with one pre-filled syringe from the package. Keep all remaining syringes in the box.
  • If your syringe has been stored in the refrigerator, take the blister containing the syringe out at least 20 minutes before you will inject the medicine so that it warms up to room temperature.

Wash your hands thoroughly with soap and water.

If you wish to use an injection device to make your injection, the MyJECT device can be used with Brabio. The MyJECT device is only approved to be used with Brabio and has not been tested with other products. Please refer to the instructions for use provided with the MyJECT injection device.

Choose the injection site, within the area, using the diagrams.

There are seven possible areas on your body for injection:

Area 1: stomach area (abdomen) around the belly button. Avoid 5 cm around the belly button,

Area 2 and 3: Thighs (above your knees),

Area 4, 5, 6 and 7: Back of the upper arms, end of upper hips (below your waist).

Within each injection area there are several injection sites. Choose a different site for the injection every day. This will reduce the likeliness of any irritation or pain at the site of the injection. Rotate the injection sites within an area. Do not use the same site each time.

Please note: do not inject in any area that is painful or discoloured or where you feel firm knots or lumps. You should consider having a planned schedule for rotating injection sites and making a note of it in a diary. There are some sites on your body that may be difficult for self-injection (like the back of your arm). If you want to use these, you may require assistance.

How to inject:

  • Remove the syringe from its protective blister by peeling back the blister lid.
  • Remove the shield from the needle, do not remove the shield with your mouth or teeth.
  • Gently pinch up the skin with the thumb and forefinger of the free hand (Figure 1).
  • Push the needle into the skin as shown in

    Figure 2.

  • Inject the medicine by steadily pushing the plunger all the way down until the syringe is empty.
  • Pull the syringe and needle straight out.
  • Discard the syringe in a safe disposal container. Do not put used syringes into the household waste but dispose of them carefully in a puncture-proof container as recommended by your doctor or nurse.

    Figure 1 Figure 2 If you have the impression that the effect of Brabio is too strong or too weak, talk to your doctor.

If you use more Brabio than you should

Talk to your doctor immediately.

If you forget to use Brabio

Use it as soon as you remember or are able to use it, then skip the following day. Do not use a double dose to make up for forgotten individual doses. If possible you should return to your regular administration schedule the following week.

V3 MAY 2023

Date: Time:

DescriptionBrabio_40mg_1ml_40mg_ml_12
LeafletSite Barcode/N/ANo. of colours1Page Count2 of 2
ART-162-06Viatris SAP No.400534363
ART-162-05120880878/0020
ART-162-061
MA No.PL 04569/1756United Kingdomwith
Supplier SAP No.N/AN/A
New Supplier Code381405-093D Render IDN/AMain FontMyriad Pro10.5 pt
381405-08160 x 560 mm10.5 pt
Synthon Chile Ltda (Santiago - CL)Keyline/Drawing No.2600_lf_160x560_v1
Sign-offs

10 Oct 24 00:26

DataMatrix

If you stop using Brabio

Do not stop using Brabio without consulting your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions (hypersensitivity, anaphylactic reaction)

You may develop a serious allergic reaction to this medicine shortly after administration. This is an uncommon side effect. These reactions may occur months up to years after starting treatment with Brabio, even if previous administrations were without allergic reactions.

Stop using Brabio and contact your doctor immediately or go to the emergency department at your nearest hospital, if you notice any sudden sign of these side effects:

  • widespread rash (red spots or nettle rash),
  • swelling of the eyelids, face, lips, mouth,

    throat or tongue,

  • sudden shortness of breath, difficulty

    breathing or weezing,

  • convulsions (fits),
  • trouble swallowing or speaking,
  • fainting, feeling dizzy or faint,
  • collapse.

Other reactions following Injection (Immediate post-injection reaction)

Some people may get one or more of the following symptoms within minutes after injecting glatiramer acetate. They normally do not cause any problems and usually disappear within half an hour.

However, if the following symptoms last longer than 30 minutes, tell your doctor immediately or go to the casualty department at your nearest hospital:

  • flushing (reddening) of the chest or face

    (vasodilatation),

  • shortness of breath (dyspnoea),
  • chest pain
  • pounding and rapid heartbeat

    (palpitations, tachycardia).

Liver problems

Liver problems or worsening of liver problems, including liver failure (some cases resulting in liver transplantation), can occur rarely with Brabio.

Contact your doctor right away if you have symptoms such as:

  • nausea,
  • loss of appetite,
  • dark colored urine and pale stools,
  • yellowing of your skin or the white part of

    your eye,

  • bleeding more easily than normal. In general the side effects reported by patients using glatiramer acetate 40 mg/ml three times a week were also reported in patients who used glatiramer acetate 20 mg/ml (see the following list). The following side effects have been reported with glatiramer acetate: Very common (may affect more than 1 in 10 people)

Infections, flu • anxiety, depression • headache

  • feeling sick • skin rash • pain in the joints or back • feeling weak, skin reactions at the injection site including reddening of skin, pain, formation of wheals, itching, tissue swelling, inflammation and hypersensitivity (these injection site reactions are not unusual and normally decrease over time), non-specific pain

Common (may affect up to 1 in 10 people) Inflammation of the respiratory tract, gastric flu, cold sore, inflammation of the ears, runny nose, tooth abscess, vaginal thrush

  • non-malignant skin growth (non-malignant neoplasm of skin), tissue growth (neoplasm)
  • lymph node swelling • allergic reactions
  • loss of appetite, weight gain • nervousness
  • altered taste, increased tightness of muscle tone, migraine, speech disorder, fainting, tremor • double vision, eye disorder • ear disorder • cough, hay fever • disorder of anus or rectum, constipation, tooth decay, indigestion, difficulty in swallowing, bowel incontinence, vomiting • abnormal liver function test • bruising, excessive sweating, itching, skin disorder, nettle rash • neck pain • urge to empty your bladder, frequent urination, inability to empty your bladder appropriately • chill, face swelling, wasting of tissue under the skin at injection site, local reaction, peripheral swelling due to build-up of fluid, fever

Uncommon (may affect up to 1 in 100 people)

Abscess, inflammation of skin and the soft tissue underneath, boils, shingles, inflammation of kidney

  • skin cancer • increased white blood cell count, reduced white blood cell count, spleen enlargement, low blood platelet count, change in form of white blood cells
  • enlarged thyroid, overactive thyroid • low alcohol tolerance, gout, increase in blood fat levels, increase in blood sodium, decrease in serum ferritin • abnormal dreams, confusion,

    euphoric mood, seeing, hearing, smelling, tasting or feeling something that is not there (hallucinations), aggression, abnormal elevated mood, personality disorder, suicide attempt

    • hand numbness and pain (carpal tunnel syndrome), mental disorder, fits (convulsion), problems with handwriting and reading, muscle disorders, problems with movement, muscle spasm, nerve inflammation, abnormal nerve-muscle link leading to abnormal muscle function, involuntary rapid movement of the eyeballs, paralysis, foot drop (peroneal nerve palsy), unconscious state (stupor), visual blind spots • cataract, eye lesion in the cornea, dry eye, eye bleeding, droopy upper eyelid, pupil widening, wasting of the optic nerve leading to visual problems • extra heart beats, slow heart beats, episodic fast heart beats
    • varicose vein • periodic stops in breathing, nose bleeding, abnormally fast or deep breathing (hyperventilation), tight feeling in the throat, lung disorder, inability to breath due to throat tightness (choking sensation)
    • bowel inflammation, polyps in the colon, intestine inflammation, burping, ulcer in the gullet, inflammation of the gums, rectal bleeding, enlarged salivary glands • gallstones, liver enlargement • swelling of the skin and soft tissues, skin contact rash, painful red skin lumps, skin lumps • swelling, inflammation and pain of joints (arthritis or osteoarthritis), inflammation and pain of fluid-sacs lining the joint (exist in some of the joints), flank pain, decrease in the mass of muscles • blood in the urine, kidney stones, urinary tract disorder, urine abnormality • breast swelling, difficulties getting an erection, fall down or slip out of the place of pelvic organs (pelvic prolapse), sustained erections, disorders of prostate, abnormal PAP smear test (Smear Cervix Abnormal), testes disorder, vaginal bleeding, vaginal disorder • cyst, hangover, low body temperature (hypothermia), non-specific inflammation, destruction of tissue at the injection site, problems with mucous membranes • disorders after vaccination Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Brabio

Keep this medicine out of the sight and reach of children.

Store in a refrigerator (2°C - 8°C).

Brabio pre-filled syringes can be kept for up to one month outside the refrigerator between 15°C and 25°C. You can do this only once. After one month any Brabio pre-filled syringes that have not been used and are still in their original packaging must be returned to the refrigerator.

Do not freeze.

Keep the pre-filled syringes in the outer carton in order to protect from light. Do not use this medicine after the expiry date which is stated on the label and carton after ‘EXP’. The first two digits indicate the month and the last four digits indicate the year. The expiry date refers to the last day of that month.

Dispose of any syringes that contain particles. Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Brabio contains

  • The active substance is glatiramer acetate.

    1 ml solution for injection (the contents of one pre-filled syringe) contains 40 mg glatiramer acetate.

  • The other excipients are mannitol and water for injections.

What Brabio looks like and contents of the pack

Brabio solution for injection in pre-filled syringe is a sterile, clear colourless to slightly yellow/brownish solution.

If the solution contains particles, throw it away and start again. Use a new syringe. 3 pre-filled syringes

12 pre-filled syringes

36 (3x12) pre-filled syringes

Not all pack sizes may be marketed. Marketing Authorisation Holders:

Mylan, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom.

Manufacturers:

Synthon Hispania SL

Castelló 1, Poligono Las Salinas,

08830 Sant Boi de Llobregat, Spain Synthon BV

Microweg 22, 6545 CM Nijmegen,

The Netherlands

This leaflet was last revised in 11/2024.

381405-09 ART-162-06

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 04569/1756

Last revision stated in the text: November 2024 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Brabio 40 mg / ml solution for injection Pre-filled syringe

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Glatiramer
Strength 40 mg / ml
Pharmaceutical form Solution for injection
Clear colourless to slightly yellow/brownish solution free from visible particles. The solution for injection has a pH of 5.5 - 7.0 and an osmolarity of about 300 mOsmol/L.
How is it taken Subcutaneous
Excipients Mannitol, Water for injections
Pack sizes 12 pre-filled disposable injection
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years.
Storage Store in the original package in order to protect from light.
Store in a refrigerator (2°C to 8°C).
Do not freeze.
If the pre-filled syringes cannot be stored in a refrigerator, they can be stored between15°C and 25°C, once, for up to one month.
After this one month period, if the glatiramer acetate pre-filled syringes have not been used and are still in their original packaging, they must be returned to storage in a refrigerator (2°C to 8°C).
Drug group (ATC) Antineoplastic and immunomodulating agents, other immunostimulants
  1. L Antineoplastic and immunomodulating agents
    1. L03 Immunostimulants
      1. L03A Immunostimulants
        1. L03AX Other immunostimulants
          1. L03AX13 glatiramer acetate
Marketing authorisation PL 04569/1756 (first authorised 28 August 2024)
Marketing authorisation holder Generics [UK] Limited t/a Mylan
Codes GTIN 5016695007472 · BNF 08020400

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.1.0 of 12 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.